TO THE EDITOR:
Viral upper respiratory infections (vURIs) are common in children. The effect of vURI at the time of liver transplantation (LT) on the postoperative outcomes is unknown. At a large quaternary referral center, preoperative viral screening tests by rapid enzyme immunoassay (EIA) and polymerase chain reaction (PCR) are performed routinely as patients present for LT, regardless of clinical appearance. Although a positive rapid EIA for respiratory syncytial virus (RSV) or influenza may preclude transplant, these screens are poorly sensitive. Moreover, the results of the molecular tests are often delayed and therefore cannot impact the clinical decision to proceed with organ transplant. The aim of this study is to begin to describe the impact of vURI on post-LT outcomes in children.
Patients and Methods

STUDY COHORT
After approval from our institutional review board, the medical record for each patient who received LT at Texas Children's Hospital from February 2009 to June 2016 was reviewed for vURI test results from samples collected during the peritransplant period, defined as between 24 hours before LT and 72 hours after LT. Each patient received pre-LT rapid tests for RSV and influenza A/B by EIA as well as some combination of viral culture or PCR for selected respiratory pathogens. Post-LT viral testing was conducted based on clinical suspicion. Patients were included for analysis if they underwent isolated LT during the study period with no prior history of solid organ transplant.
DATA AND OUTCOMES
Included patients were characterized based on demographics and clinical presentation. Positive upper respiratory infection (URI) cohort data and outcomes were compared with those patients who had negative laboratory evidence for vURI. Primary clinical outcomes were posttransplant length of stay (LOS), graft loss due to hepatic artery thrombosis (HAT) requiring retransplantation, and patient survival.
INSTITUTIONAL APPROACH TO HAT PREVENTION AND MANAGEMENT
HAT prevention protocol at our institution is individualized for each patient and consists of a heparin drip for the first few days after LT with transition to lovenox or aspirin for high-risk patients (as defined by intraoperative considerations such as surgical approach, small hepatic artery caliber, and low patient weight). Once the diagnosis of HAT is made, thrombectomy is attempted. If this approach fails in the setting of significant graft dysfunction, the patient is listed for retransplantation.
STATISTICAL ANALYSIS
Continuous variables were compared with the MannWhitney U test and are reported as median with interquartile range (IQR). Categorical variables were compared using the Pearson chi-square test and are reported as numbers and percentages. Variables found to be statistically significant on univariate analysis (P < 0.05) were also analyzed by multivariate logistic regression. Graft survival was determined using the Kaplan-Meier curve and log-rank test. Statistical significance was set to P < 0.05. Analysis was performed 
Results
A total of 222 patients were included in the study. Each underwent first LT during the study period. Including subsequent retransplantation, 232 LTs were performed for included patients during this time. Nine patients were excluded from the study due to multiorgan transplant (n 5 5), history of previous LT (n 5 1), or lack of laboratory records for vURI therefore precluding group assignment (n 5 3). Of 222 patients, 12 (5.4%) were found to have laboratory evidence of vURI during the peritransplant period. The individualized characteristics of the 12 patients with laboratorydocumented vURI are summarized in Table 1 . Of the 12 patients with detected peritransplant URI, 8 demonstrated symptoms typical of viral infection in the 2 weeks prior to transplant as documented by the medical records on either review of systems or physical examination. One patient had a documented isolated temperature of 38.0 8C preoperatively. Pre-LT chest radiographs were without acute abnormality or compelling evidence of lower respiratory tract disease. As shown in Table 2 , patients with URI did not differ from URI-negative controls in age, sex, weight, liver disease score, or primary liver diagnosis. However, there was an increase in pre-LT international normalized ratio of prothrombin time (PT-INR; P 5 0.04) and bilirubin (P 5 0.005) as well as a decrease in albumin (P 5 0.02) for the URI-positive group. The positive URI group was also characterized by fewer home admits (P 5 0.004) and more intensive care unit (ICU) inpatients (P 5 0.009) at LT. There was no difference in mechanical ventilation or dialysis use between groups. Analysis of donor factors showed no difference in donor age, body mass index (BMI), the type of graft used (split versus whole organ), cytomegalovirus (CMV) or Epstein-Barr virus (EBV) mismatch (defined as the use of a seropositive donor graft to a seronegative recipient), or cold ischemia time.
For our outcomes analysis, median follow-up time for 222 patients was 3.0 years (IQR, 1.2-5.0 years). Incidence of and timeline to all-cause graft loss according to vURI status is shown in Fig. 1A . The presence of vURI was associated with all-cause graft failure (P 5 0.008). Graft failure in the URI-positive cohort occurred within 30 days after LT, and in 3 of 4 patients was due to HAT. To demonstrate this association, Fig. 1B shows that early hepatic artery thrombosis (eHAT), defined as HAT within 30 days after transplant, requiring retransplantation was also associated with presence of vURI (P < 0.001). Table 3 illustrates a comparison of our selected outcomes at 1 month after LT as well as overall patient survival with corresponding P values. Peritransplant URI was associated with all-cause and HAT-related graft loss as well as prolonged post-LT LOS. Overall, 33.3% (4/12) of the positive URI cohort had graft failure compared with 4.8% (10/210) of the control group (P < 0.001), and 25% (3/12) of the positive URI cohort suffered early HAT leading to graft loss and retransplantation whereas 2.9% (6/210) of the control group had this complication (P < 0.001). None of the 3 patients excluded from analysis due to missing institutional data had HAT. Additionally, vURI was associated with increased post-LT LOS (P 5 0.008). For the overall follow-up time given, there was no difference in incidence of patient death between groups. On multivariate logistic regression analysis, the presence of peritransplant URI was independently associated with both all-cause graft loss at 1 month and eHAT as shown in Table 4 .
Discussion
This pediatric study indicates that vURI is not uncommon in the peritransplant period. The majority of patients in our cohort were symptomatic for vURI during the period leading up to transplant though clinically well enough to proceed with LT. However, given the observations in our present study, viral URI may contribute to graft failure due to eHAT in children. The true cause of HAT remains incompletely described. However, it is known that the incidence of HAT is nearly 3 times greater in pediatric patients than in adults.
(1) Risk factors that have been concordantly reported to contribute to the discrepancy between pediatric and adult populations include CMV mismatch, regrafts, low recipient weight, variant arterial anatomy, prolonged operation time, and the technical challenges associated with pediatric LT. (1) (2) (3) Several studies published over the last 3 decades have stressed the importance of attenuating the coagulation cascade in pediatric patients in order to decrease incidence of HAT. (4, 5) The present study demonstrates that HAT occurred within 30 days of LT, suggesting that this event may be related to factors proximal to surgery such as a procoagulant state secondary to infection. Visseren et al. demonstrated that respiratory viruses including influenza A/B, RSV, adenovirus, and parainfluenza are able to infect human umbilical vein endothelial cells and induce procoagulant effects in vitro. (6) It is possible that virus-related procoagulant effects may contribute to our observations of increased HAT. The evidence provided in the present study also demonstrates an increase in post-LT LOS in the presence of peritransplant vURI. This difference may be attributable in part to pathophysiological factors related to vURI or may reflect the increased morbidity in the cohort.
Our small sample size limits this study. A multicenter study may allow us to create a more robust analysis and provide a better ability to describe associations made in the present study. In addition, we have not yet evaluated the role of intraoperative considerations in HAT risk. Future analysis at our institution may describe these factors as well as include a comparison of ICU and pulmonary outcomes.
In light of the association our study demonstrates, we propose that perhaps more rapid and clinically relevant viral testing should be considered in patients who display symptoms of vURI before LT. Given the limited donor pool, graft loss to a condition that has potentially modifiable risk factors is a tragedy. In lowacuity patients, perhaps LT may be deferred until resolution of a viral illness. In patients who require urgent LT or who have multiple risk factors for HAT, perhaps more aggressive monitoring for HAT may be warranted. Additionally, because many of the patients with vURI were inpatients at the time of organ allocation, standard contact precautions and minimizing contact with potentially infectious persons may become paramount in LT candidates in order to prevent health care-associated viral infection. Our findings represent a potential novel consideration to an important multifactorial complication. Existing literature evaluating the presence of vURI in pediatric transplant recipients is sparse; future studies should focus on further elucidating the relationship between vURI at the time of LT and HAT. Ultimately, we advise that clinical judgment must be used when weighing the risks and benefits of LT in the setting of possible vURI.
